Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Progress For Africa, As First Internal mAb Biosimilar Trialed In Europe

Proposed Adalimumab Biosimilar Adessia Dosed Last Month In Germany

Executive Summary

The quality of analytical data obtained so far and accepted by the German Federal Ministry of Health’s Paul-Ehrlich Institute has been praised as part of the step forward.

You may also be interested in...



Alvotech Taps Equity Financing As Venture Bears Fruit In Saudi Arabia

Alvotech has once again raised more than $100m in financing, the second time in a matter of months, via a private placement involving what it expects to be previously issued treasury shares held by one of its subsidiaries.

Minapharm acquires ProBioGen for €30 million

Minapharm Pharmaceuticals of Egypt has acquired 95% of the share capital of the privately held German firm ProBioGen for €30.4 million, which includes earn-out payments that are conditional on achieving certain milestones.

Dr Reddy’s Can Still Go It Alone After Penning Orencia Biosimilar Deal

Targeting a dual biologic for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, Coya Therapeutics has joined forces with abatacept biosimilar developer Dr Reddy’s.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel